drugset / Trial / NCT05613803
Poly-unsaturated Fats for Improving Nasal Polyps and Asthma
Phase 3
Completed
18 enrolled
Norfolk and Norwich University Hospitals NHS Foundation Trust
University of East Anglia · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Asthma is a syndrome compromising many phenotypes including N-ERD (caused by increased 4-series leukotriene (LT) production). n-3 PUFA supplementation modulates 4-series LT and has anti-inflammatory effects. However, other than in a pilot study with dietary manipulation, the effects of N-ERD are unknown. The primary objective is to determine whether n-3 PUFA supplementation in people with N-ERD can improve asthma control using the asthma control questionnaire (ACQ-7). This is a placebo controlled randomised controlled parallel multicentre study with of 6g per day of PUFA for 6 months in people with N-ERD and poor asthma control
Timeline
- Start
- 2023-10-09
- Primary completion
- 2026-01-31
- Completion
- 2026-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fish oil | Other / unclassified | 6 g | Oral |